Sagimet Biosciences’ (SGMT) “Buy” Rating Reiterated at HC Wainwright

Sagimet Biosciences (NASDAQ:SGMT)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $29.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 226.58% from the company’s current price. HC Wainwright also issued estimates for Sagimet Biosciences’ Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.31) EPS, FY2027 earnings at ($1.03) EPS, FY2028 earnings at ($0.64) EPS, FY2029 earnings at $0.89 EPS and FY2030 earnings at $2.28 EPS.

Several other analysts have also weighed in on SGMT. Wall Street Zen lowered Sagimet Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. The Goldman Sachs Group started coverage on Sagimet Biosciences in a research report on Thursday, September 24th. They set a “sell” rating and a $7.00 price target on the stock. Barclays raised Sagimet Biosciences from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $8.00 to $18.00 in a research report on Wednesday, September 9th. Oppenheimer upped their target price on Sagimet Biosciences from $33.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, October 1st. Finally, Citizens Jmp dropped their target price on Sagimet Biosciences from $29.00 to $27.00 and set a “market outperform” rating on the stock in a research report on Thursday, October 1st. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Sagimet Biosciences currently has an average rating of “Moderate Buy” and an average price target of $26.63.

Sagimet Biosciences Trading Up 1.4%

Shares of SGMT stock traded up $0.12 during mid-day trading on Monday, reaching $8.88. The stock had a trading volume of 121,117 shares, compared to its average volume of 1,194,791. The company has a market cap of $551.98 million, a P/E ratio of -6.92 and a beta of 3.46. Sagimet Biosciences has a 12-month low of $4.50 and a 12-month high of $11.45. The business has a 50-day simple moving average of $9.89 and a 200 day simple moving average of $7.83.

Sagimet Biosciences (NASDAQ:SGMT) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). Research analysts anticipate that Sagimet Biosciences will post -1.17 EPS for the current year.

Insider Activity at Sagimet Biosciences

In related news, CEO David Happel sold 64,051 shares of the firm’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $7.76, for a total transaction of $497,035.76. Following the completion of the sale, the chief executive officer directly owned 741,570 shares of the company’s stock, valued at $5,754,583.20. This trade represents a 7.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 20,206 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $9.95, for a total value of $201,049.70. Following the sale, the director directly owned 62,161 shares of the company’s stock, valued at $618,501.95. This represents a 24.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 113,646 shares of company stock valued at $920,491 in the last three months. Corporate insiders own 11.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its stake in shares of Sagimet Biosciences by 82.6% in the 1st quarter. Renaissance Technologies LLC now owns 625,469 shares of the company’s stock valued at $3,268,000 after purchasing an additional 282,969 shares during the period. Seven Fleet Capital Management LP acquired a new stake in shares of Sagimet Biosciences in the 2nd quarter valued at about $3,119,000. Dimensional Fund Advisors LP raised its stake in shares of Sagimet Biosciences by 99.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 271,217 shares of the company’s stock valued at $1,415,000 after purchasing an additional 135,178 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Sagimet Biosciences in the 2nd quarter valued at about $1,551,000. Finally, AWM Investment Company Inc. acquired a new stake in shares of Sagimet Biosciences in the 2nd quarter valued at about $618,000. 87.86% of the stock is currently owned by institutional investors.

Key Stories Impacting Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: HC Wainwright raised its EPS estimates for Q4 2026 to $(0.27) from $(0.32), FY2026 to $(1.31) from $(1.48), FY2027 to $(1.03) from $(1.22), and FY2028 to $(0.64) from $(0.85). These smaller projected losses suggest improving operating expectations and may support SGMT’s shares. HC Wainwright Has Optimistic Opinion of SGMT FY2026 Earnings
• Positive Sentiment: The analyst also increased its FY2029 EPS forecast to $0.89 from $0.81, indicating a potential transition to profitability. HC Wainwright’s $29 target implies substantial upside from recent trading levels. HC Wainwright Has Strong Forecast for SGMT FY2029 Earnings
• Neutral Sentiment: HC Wainwright slightly reduced its FY2030 EPS forecast to $2.28 from $2.34, but the estimate still implies continued profitability and represents only a modest adjustment. HC Wainwright Has Strong Forecast for SGMT FY2029 Earnings
• Negative Sentiment: SGMT has recently experienced notable share-price weakness, underscoring investor volatility and the risks associated with a biotechnology company that remains loss-making in the near term. Sagimet Biosciences Shares Down 6% – What’s Next?

Sagimet Biosciences Company Profile

Sagimet Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target fatty acid synthase (FASN), an enzyme involved in the production of fatty acids. The company’s research is aimed at treating diseases associated with abnormal lipid metabolism and excess fat production.

Sagimet’s lead investigational product is denifanstat, an oral, selective FASN inhibitor formerly known as TVB-2640. The company is evaluating denifanstat primarily for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that can involve inflammation, fat accumulation and fibrosis.